Sign in
WithdrawnPhase 1

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

Key facts

Who runs it
National Institute of Mental Health (NIMH)
Where
Bethesda, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1
Started
26 Feb 2025
Ended
26 Feb 2025
Type of study
Interventional, 3 groups
Treatments tested
  • MRI
  • MagPro TMS stimulator and coil
  • Thymatron (R) System IV paired with 4X1 HDECT
Record updated
27 February 2025
Why it stopped
PI leaving NIH.

Who can take part

Age
22 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (21)Hide the full registry criteria

Who cannot take part

  • Increased risk of complications from seizures, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication at a dose that significantly alters seizure threshold, as determined by the investigators
  • Subjects with any of the following treatment histories:; Failure to respond to ECT treatment (i.e., consistent with ATHF confidence level 3 or higher) in this or any previous episode; Lifetime history of treatment with Deep Brain Stimulation or Vagus Nerve Stimulation; Use of any investigational drug or device within 4 weeks of the screening
  • Current serious medical illness, such as high blood pressure, diabetes, heart or lung disease that is not controlled by treatment and/or judged by the investigators to significantly affect the validity of the study or the safety of study participation
  • History of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, concussion resulted in loss of consciousness or hospitalization, cranial metal implants that are not safety-compatible with magnetic resonance imaging (MRI) and/or electroconvulsive therapy (ECT), known structural brain lesion, devices that may be affected by TMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain stimulator, vagus nerve stimulator)
  • Diagnosed with the following conditions (current unless otherwise stated):; Any other current primary mood, anxiety, or psychotic disorder; Depression secondary to a general medical condition, or substance-induced; Psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in the current episode; Eating disorder (current or within the past year); Obsessive compulsive disorder (current or within the past year); Post-traumatic stress disorder (current or within the past year); ADHD (currently being treated); Subjects meeting criteria of any psychiatric illness based upon DSM-5, which in the judgment of the Investigator, may hinder the subjects in completing the procedures required by the study protocol; Actively suicidal
  • Subjects with a clinically defined neurological disorder including, but not limited to:; Any condition likely to be associated with increased intracranial pressure; Space occupying brain lesion; History of stroke; Transient ischemic attack within two years; Cerebral aneurysm; Dementia; Mini Mental Status Exam (MMSE) score < 24; Parkinson s disease; Huntington s disease; Multiple sclerosis
  • A history of claustrophobia that may make it difficult for the patient to complete the MRI study or may adversely impact the quality of the images or the interpretation of the findings
  • Current visual, auditory, or motor impairment that compromises ability to complete evaluations
  • Positive HIV test
  • Pregnant or nursing women or women who plan to become pregnant during the study period
  • Current or recent (within the past 6 months) substance abuse or dependence (excluding nicotine and caffeine)
  • Subjects with:; intracranial metal that are not safety-compatible with MRI and/or ECT, and/or; extracranial metal, that are not safety-compatible with MRI and/or ECT
  • NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy

Other criteria

  • INCLUSION CRITERIA:
  • Male and female, 22-70 years old
  • Use of effective method of birth control for women of childbearing capacity. Women who are able to get pregnant must be willing to use at least one form of effective birth control during the entire period of study participation (or until last clinical labs and rating) and have a negative pregnancy test at screening
  • DSM-5 diagnosis of major depressive disorder, confirmed by the structured clinical interview for the DSM 5 (SCID)
  • Eligible for ECT, including patients receiving maintenance ECT
  • Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document
  • Subjects are willing and able to adhere to the intensive treatment schedule and all required study procedures
  • On a stable dose of all psychotropic medications (no new medications, discontinuations or dose changes) for 4 weeks prior to baseline assessment and agreement not to change psychotropic medications during the experimental phase (Phase II) of the study, unless advised otherwise by the Investigator

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United States

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Electroconvulsive therapy (ECT) is used to treat people with severe depression. During ECT, the brain is given electric pulses that cause a seizure. Although it is effective, it can cause side effects, including memory loss. Researchers want to study a new way to give ECT called iLAST.

Objective:

To see if iLAST is safe and feasible in treating depression.

Eligibility:

People ages 22 70 years old who have major depressive disorder and are eligible for ECT

Design:

Participants will be screened under protocol 01-M-0254. This includes:

Medical and psychiatric history and exam

Blood and urine tests

Participants will be inpatients at the Clinical Center. They study has 3 phases and will last up to 20 weeks.

Phase I will last 1 week. It includes:

MRI: Participants will lie in a scanner that takes pictures of the body

MEG: A cone over the participant s head will record brain activity.

TMS: A wire coil placed on the participant s scalp will produce an electrical current to affect brain activity.

SEP: An electrode on the participant s wrist will give a small electrical shock to test nerve function.

Phase II will last 2 and a half weeks. It includes:

Seven sessions of iLAST under general anesthesia. Participants may also get standard ECT.

EEG: A small electrode placed on the participant s scalp will record brain waves.

Interviews about mood, symptoms, and side effects. Participants facial expressions may be video recorded.

TMS

Phase III will last at least 1 week. It will include:

MRI

EEG

TMS

MEG

Standard ECT if needed. Participants will have sessions every other day, 3 times a week.

The 3 groups in the trial

  • ECTTreatment being tested

    ECT treatment, Within subject cross-over

    Treatment: Thymatron (R) System IV paired with 4X1 HDECT

  • MRITreatment being tested

    Structural and functional neuroimaging pre and post ECT treatment

  • TMSTreatment being tested

    Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment

    Treatment: MagPro TMS stimulator and coil

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)
Record updated
27 February 2025